CN114466863A - 百日咳毒素结合蛋白 - Google Patents

百日咳毒素结合蛋白 Download PDF

Info

Publication number
CN114466863A
CN114466863A CN202080049059.3A CN202080049059A CN114466863A CN 114466863 A CN114466863 A CN 114466863A CN 202080049059 A CN202080049059 A CN 202080049059A CN 114466863 A CN114466863 A CN 114466863A
Authority
CN
China
Prior art keywords
seq
single variable
variable domain
immunoglobulin single
domain comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080049059.3A
Other languages
English (en)
Inventor
徐霆
汪皛皛
王玲
朱丹明
高丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Alphamab Co Ltd
Original Assignee
Suzhou Alphamab Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Alphamab Co Ltd filed Critical Suzhou Alphamab Co Ltd
Publication of CN114466863A publication Critical patent/CN114466863A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1225—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Bordetella (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/235—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Bordetella (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

提供了针对百日咳毒素(PT)的单域抗体、人源化单域抗体、其衍生蛋白及其用途。

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN202080049059.3A 2019-07-01 2020-07-01 百日咳毒素结合蛋白 Pending CN114466863A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019105841557 2019-07-01
CN201910584155 2019-07-01
PCT/CN2020/099691 WO2021000886A1 (zh) 2019-07-01 2020-07-01 百日咳毒素结合蛋白

Publications (1)

Publication Number Publication Date
CN114466863A true CN114466863A (zh) 2022-05-10

Family

ID=74100292

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080049059.3A Pending CN114466863A (zh) 2019-07-01 2020-07-01 百日咳毒素结合蛋白

Country Status (5)

Country Link
US (1) US20230061378A1 (zh)
EP (1) EP3995510A4 (zh)
JP (1) JP7315259B2 (zh)
CN (1) CN114466863A (zh)
WO (1) WO2021000886A1 (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459183A (zh) * 2014-03-31 2017-02-22 德克萨斯大学系统董事会 人源化百日咳抗体及其用途
US20180118817A1 (en) * 2016-08-15 2018-05-03 Board Of Regents, The University Of Texas System Bispecific pertussis antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
ES2162823T5 (es) 1992-08-21 2010-08-09 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
CA2752396A1 (en) 2010-09-17 2012-03-17 Board Of Regents, The University Of Texas System Pertussis antibodies and uses thereof
CN102558355B (zh) 2011-12-31 2015-02-25 苏州康宁杰瑞生物科技有限公司 基于电荷网络的异二聚体fc改造方法及异二聚体蛋白的制备方法
CN102851338A (zh) 2012-07-25 2013-01-02 苏州康宁杰瑞生物科技有限公司 利用电荷排斥作用制备同二聚体蛋白混合物的方法
CN105039259A (zh) * 2015-07-10 2015-11-11 北京科兴中维生物技术有限公司 百日咳杆菌pt抗原单克隆抗体及其应用
CN108254556B (zh) * 2018-03-15 2020-10-30 北京科兴中维生物技术有限公司 一种百日咳毒素检测试剂盒及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459183A (zh) * 2014-03-31 2017-02-22 德克萨斯大学系统董事会 人源化百日咳抗体及其用途
US20180118817A1 (en) * 2016-08-15 2018-05-03 Board Of Regents, The University Of Texas System Bispecific pertussis antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PETER WILLIAMSON等: "Development of neutralising human recombinant antibodies to pertussis toxin", 《FEMS IMMUNOLOGY & MEDICAL MICROBIOLOGY》, vol. 23, no. 4, pages 313 *
张雨笑: "抗百日咳毒素单克隆抗体及其应用研究进展", 《微生物学免疫学进展》 *

Also Published As

Publication number Publication date
WO2021000886A1 (zh) 2021-01-07
JP7315259B2 (ja) 2023-07-26
EP3995510A4 (en) 2023-11-08
JP2022538438A (ja) 2022-09-02
EP3995510A1 (en) 2022-05-11
US20230061378A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
EP3838289A1 (en) Anti-tigit antibody and uses thereof
JP2020537509A (ja) Ｔｉｇｉｔ抗体、その抗原結合断片及びその医療用途 本願は、２０１９年９月２９日に出願された出願番号ｃｎ２０１７１０９０８５６５．３に基づいたものであり、その優先権を主張する。その開示は、その全体が参照により本明細書に組み込まれる。
CN111902428B (zh) 一种双特异性抗体及其用途
JP2019511201A (ja) 前立腺特異的膜抗原（ｐｓｍａ）と結合する分子
US20210363266A1 (en) Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof
CN111683966A (zh) 与cd22结合的重链抗体
EP3730518A1 (en) Monoclonal antibody binding to human il-5, preparation method therefor and use thereof
CN114685666B (zh) 抗间皮素纳米抗体及其应用
CN117843803A (zh) 新型串联单域抗体及其在疾病治疗中的应用
US20220340657A1 (en) Antibody and bispecific antibody targeting lag-3 and use thereof
TW202031686A (zh) 抗ｃｄ７９ｂ抗體、其抗原結合片段及其醫藥用途
EP4365202A1 (en) Anti-trop2 single-domain antibody and use thereof
EP4177275A1 (en) Coagulation factor xi (fxi) binding protein
US20230265181A1 (en) Single variable domain and antigen binding molecule binding bcma
WO2021000886A1 (zh) 百日咳毒素结合蛋白
CN116897053A (zh) 含抗tslp抗体的药物组合物
EP4202047A1 (en) Bcma-binding single variable structural domain and antigen-binding molecule
TWI827980B (zh) 結合人il-33的抗體、其製備方法和用途
US20240010730A1 (en) Bispecific antibody and use thereof
WO2023025249A1 (zh) 一种含融合蛋白的药物组合物
WO2024002145A1 (zh) 结合il-17a和il-17f的抗体分子及其应用
CN117986361A (zh) 一种gipr结合蛋白及其应用
TW202409074A (zh) 鬆弛素或類似物的融合蛋白及其醫藥用途
CN117886942A (zh) 抗人msln抗体及其应用
CN117843779A (zh) 抗体、核酸、药物制剂和炎性疾病治疗方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination